<DOC>
	<DOCNO>NCT02475200</DOCNO>
	<brief_summary>The Phoenix Post-Approval Registry prospective , multi-center , single arm registry sponsor Volcano Corporation evaluate short long term performance clinical outcome Phoenix Atherectomy System .</brief_summary>
	<brief_title>Phoenix Post-Approval Registry - Using Phoenix Atherectomy Systems</brief_title>
	<detailed_description>The Phoenix Post-Approval Registry prospective , multi-center , single arm registry , sponsor Volcano Corporation , evaluate short long term performance clinical outcome Phoenix Atherectomy System . The study include consecutive patient treat Phoenix Atherectomy System post-market ( commercial device use ) setting . Patients follow real-world condition 12 month index procedure . All patient plan endovascular revascularization procedure receive treatment Phoenix Atherectomy System part PAD treatment strategy may include . Written informed consent must obtain patient prior enrollment study . Enrolled patient undergo PAD treatment include Phoenix atherectomy , accord institutional local standard care . Data collection include medical record review procedure perform accord standard care .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . The patient â‰¥18 year age . 2 . Patient understands research nature study willing capable provide write informed consent . 3 . Scheduled receive treatment Phoenix Atherectomy System part PAD treatment . 4 . Meets Phoenix Atherectomy System catheter Instruction Use ( IFU ) criterion . Patients ANY follow exclusion criterion NOT eligible study : 1 . Patients unwilling unable comply protocol include 12month followup patient CLI baseline . 2 . Patient participate another device drug clinical trial interferes protocol follow schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>